Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
161
Recruiting, any sponsor type, condition "rheumatoid arthritis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting161
- Completed1,399
161 trials
Showing 1 to 25, recently updated first.
AbbVieAbbVie (ABBV)
NCT06977724 · 36 participants (planned) · Start Aug 26, 2025 · Primary completion Mar 2029
Drug: ABBV-319 · For: Dry Eye Syndrome; Systemic Lupus Erythematosus
Sites: Margate, Florida; Tampa, Florida; Orland Park, Illinois · 9 sites in all
- A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid ArthritisPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07276581 · 320 participants (planned) · Start Dec 15, 2025 · Primary completion Nov 12, 2027
Drug: AZD1163 · For: Rheumatoid Arthritis
Sites: Glendale, Arizona; Prescott Valley, Arizona; Tucson, Arizona · 147 sites in all
AbbVieAbbVie (ABBV)
NCT07607964 · 30 participants (planned) · Start May 28, 2026 · Primary completion Jan 2029
Drug: ABBV-519; ABBV-519 · For: Systemic Lupus Erythematosus; Rheumatoid Arthritis
Sites: Anniston, Alabama; Tustin, California; Clearwater, Florida · 17 sites in all
- Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)Pivotal-lookingRecruiting
Instituto de Investigación Marqués de ValdecillaAcademic, hospital or other
NCT07611747 · 1,117 participants (planned) · Start Apr 22, 2026 · Primary completion Apr 22, 2031
Drug: High-intensity lipid-lowering therapy · For: Rheumatoid Arthritis (RA); Psoriatic Arthritis (PsA); Systemic Lupus Erythematosus (SLE) and 4 more
Sites: Elche, Spain; Orihuela, Spain; Sant Joan d'Alacant, Spain · 17 sites in all
VA Office of Research and DevelopmentFederal agency
NCT06072768 · 200 participants (planned) · Start Mar 9, 2023 · Primary completion Mar 1, 2029
Drug: 15-day taper prednisone; 150-day taper prednisone · For: Rheumatoid Arthritis
Sites: Ann Arbor, Michigan · 2 sites in all
National Cancer Institute (NCI)NIH
NCT03816345 · 300 participants (planned) · Start Jul 16, 2019 · Primary completion Mar 30, 2028
Drug: Cabozantinib; Fluoropyrimidine and 4 more · For: Autoimmune Disease; Crohn Disease; Dermatomyositis and 11 more
Sites: Birmingham, Alabama; Palo Alto, California; Sacramento, California · 52 sites in all
Diabetes Free, Inc.Industry
NCT07946367 · 72 participants (planned) · Start Dec 1, 2026 · Primary completion Aug 2028
Drug: DFI205 bispecific antibody · For: Rheumatoid Arthritis (RA); Systemic Lupus Erythematosus (SLE); Systemic Sclerosis (SSc) and 1 more
Sites: Erlangen, Germany
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07412704 · 84 participants (planned) · Start Oct 6, 2026 · Primary completion Oct 30, 2029
Drug: BMS-986528 · For: Arthritis, Rheumatoid
Sites: La Jolla, California; Loma Linda, California; Palo Alto, California · 39 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07137598 · 160 participants (planned) · Start Dec 5, 2025 · Primary completion Apr 17, 2027
Drug: Afimkibart; Placebo · For: Rheumatoid Arthritis
Sites: Avondale, Arizona; Peoria, Arizona; La Jolla, California · 66 sites in all
- An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid ArthritisPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07620392 · 120 participants (planned) · Start Jun 3, 2026 · Primary completion Jul 8, 2033
Drug: Afimkibart · For: Rheumatoid Arthritis
Sites: Tamarac, Florida; Lake Charles, Louisiana; Houston, Texas · 17 sites in all
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT07171983 · 46 participants (planned) · Start Feb 27, 2026 · Primary completion Jun 28, 2027
Drug: BMS-986454 · For: Rheumatoid Arthritis
Sites: Hyderabad, India; Ahmedabad, India; Bangalore, India · 9 sites in all
Tufts Medical CenterAcademic, hospital or other
NCT06016517 · 18 participants (planned) · Start Dec 1, 2026 · Primary completion Dec 1, 2028
Drug: Etanercept; Adalimumab and 2 more · For: Arthritis, Rheumatoid
Sites: Boston, Massachusetts
AstraZenecaAstraZeneca (AZN)
NCT07295847 · 27 participants (planned) · Start Jan 9, 2026 · Primary completion Feb 22, 2028
Drug: AZD0120; SOC · For: Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Rheumatoid Arthritis
Sites: Tucson, Arizona; Duarte, California; Stanford, California · 27 sites in all
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07621809 · 570 participants (planned) · Start Jul 16, 2026 · Primary completion Aug 15, 2029
Drug: VAY736; Placebo · For: Sjögren´s Disease
Sites: Peoria, Arizona; Searcy, Arkansas; Van Nuys, California · 72 sites in all
- A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's DiseasePivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07737743 · 344 participants (planned) · Start Aug 24, 2026 · Primary completion Feb 19, 2029
Drug: DDY391; Placebo · For: Sjögren's Disease
Sites: Avondale, Arizona; Clearwater, Florida; Tampa, Florida · 31 sites in all
PTC TherapeuticsIndustry
NCT07779616 · 75 participants (planned) · Start Sep 24, 2026 · Primary completion Sep 30, 2027
Drug: PTC844; Placebo · For: Rheumatoid Arthritis
Sites: Chandler, Arizona; Flagstaff, Arizona; Phoenix, Arizona · 26 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07649265 · 63 participants (planned) · Start Sep 24, 2026 · Primary completion Nov 20, 2028
Drug: HBM7020 · For: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Systemic Sclerosis and 1 more
Sites: Brisbane, Australia
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07363590 · 21 participants (planned) · Start Feb 19, 2026 · Primary completion Jul 16, 2029
Drug: MK-1045 · For: Systemic Lupus Erythematosus; Rheumatoid Arthritis
Sites: Southport, Australia; Diepenbeek, Belgium; Ghent, Belgium · 21 sites in all
National Institute of Dental and Craniofacial Research (NIDCR)NIH
NCT07281456 · 60 participants (planned) · Start Dec 18, 2025 · Primary completion Dec 15, 2030
Drug: Tofacitinib · For: Sjogren's Syndrome
Sites: Bethesda, Maryland
Nkarta, Inc.Industry
NCT06733935 · 240 participants (planned) · Start Nov 4, 2024 · Primary completion Oct 2028
Drug: NKX019; Fludarabine and 1 more · For: Systemic Sclerosis; Idiopathic Inflammatory Myopathies; Antineutrophil Cytoplasmic Antibody-Associated Vasculitis and 1 more
Sites: Los Angeles, California; Plantation, Florida; Tampa, Florida · 12 sites in all
- Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07201558 · 48 participants (planned) · Start Dec 2, 2025 · Primary completion Jun 27, 2028
Drug: Surovatamig · For: Rheumatoid Arthritis; Systemic Lupus Erythematosus
Sites: Birmingham, Alabama; Fullerton, California; Plantation, Florida · 35 sites in all
Lubris Bio Pty LtdIndustry
NCT07118241 · 80 participants (planned) · Start Sep 17, 2025 · Primary completion Dec 30, 2026
Drug: Recombinant Human Proteoglycan 4; Vehicle Control · For: Sjögren's Syndrome
Sites: Sydney, Australia; Brisbane, Australia; Maroochydore, Australia · 7 sites in all
Antengene Biologics LimitedIndustry
NCT07732309 · 149 participants (planned) · Start Sep 26, 2026 · Primary completion Dec 1, 2028
Drug: ATG-201 · For: Systemic Lupus Erythematosus; Systemic Sclerosis (SSc); Sjogren's Disease and 1 more
Sites: Bengbu, China; Hefei, China; Beijing, China · 22 sites in all
- COVID-19 Booster and IIV Schedule in Immunocompromised HostsPivotal-lookingRecruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT06599658 · 660 participants (planned) · Start Nov 20, 2024 · Primary completion Jan 31, 2028
Drug: Inactivated influenza vaccine (IIV) at baseline; COVID-19 Vaccines at a 3-month interval and 2 more · For: COVID 19; Influenza; Rheumatoid Arthritis (RA) and 5 more
Sites: Montreal, Canada · 3 sites in all
- A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)Pivotal-lookingRecruiting
Elevara Medicines LimitedIndustry
NCT07409103 · 180 participants (planned) · Start Feb 18, 2026 · Primary completion Apr 15, 2027
Drug: ELV001 25 mg; ELV001 75 mg and 2 more · For: Active Rheumatoid Arthritis
Sites: Gilbert, Arizona; Glendale, Arizona; Tucson, Arizona · 34 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.